Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
OncoSil Medical Ltd ( (AU:OSL) ) just unveiled an announcement.
OncoSil Medical has disclosed a change in director Thomas Duthy’s indirect holdings following his participation in a recent capital raising. Through CIPA Investments Pty Ltd, Duthy acquired 50,537 new shares at $0.68 each, along with 50,537 free-attaching options exercisable at $0.90 and expiring on 30 June 2027, via a placement and entitlement offer.
As a result of the transaction, Duthy’s indirect interest increased to 91,604 shares and 223,348 options in OncoSil Medical. The placement component of his participation had been approved by shareholders at the Extraordinary General Meeting held on 12 March 2026, underscoring board and investor alignment on the company’s latest funding initiative and the director’s reinforced financial commitment.
The most recent analyst rating on (AU:OSL) stock is a Hold with a A$0.54 price target. To see the full list of analyst forecasts on OncoSil Medical Ltd stock, see the AU:OSL Stock Forecast page.
More about OncoSil Medical Ltd
OncoSil Medical Ltd is an Australian medical technology company focused on developing and commercialising implantable radiotherapy devices for the treatment of pancreatic and other solid tumour cancers. Listed on the ASX under the ticker OSL, the company targets oncology markets where targeted radiation therapies can offer improved clinical outcomes over conventional treatment options.
Average Trading Volume: 64,838
Technical Sentiment Signal: Sell
Current Market Cap: A$16.88M
Find detailed analytics on OSL stock on TipRanks’ Stock Analysis page.